Back-of-the-eye pipeline

Back-of-the-eye pipeline

Back-of-the-eye pipeline
Selected products in development for three major ophthalmic indications: diabetic macular edema (DME), age-related macular degeneration (AMD) and diabetic retinopathy (DR). (A) In October, Eli Lilly (LLY) said it would appeal FDA’s

Read the full 367 word article

How to gain access

Continue reading with a
two-week free trial.